The effect of metformin on decreasing the severity of rheumatoid arthritis

Phase 3

Recruiting

• Conditions: Rheumatoid arthritis.; Rheumatoid arthritis, unspecified; M06.9

• Registration Number: IRCT20190916044787N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients with moderate to high severity of rheumatoid arthritis based on the DAS28 scale

Exclusion Criteria

Duration of illness over 3 years
There is significant kidney disorder that forbids from using metformin (GFR <30)
Pregnancy
Significant heart failure (EF <50%)
Chronic hepatic impairment or acute liver failure
Having diabetes or previous and recent use of metformin
The last 3 months of anti-inflammatory drugs
New drug added to control patient symptoms during treatment

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease severity. Timepoint: At baseline and after treatment (12 weeks). Method of measurement: DAS28.;Erythrocyte sedimentation rate (ESR). Timepoint: At baseline and after treatment (12 weeks). Method of measurement: Western Green analysis.;Swollen joint count (SJC). Timepoint: At baseline and after treatment (12 weeks). Method of measurement: Examination and clinical judgment of the physician.;Tender joint count (TJC). Timepoint: At baseline and after treatment (12 weeks). Method of measurement: Examination and clinical judgment of the physician.;CRP. Timepoint: At baseline and after treatment (12 weeks). Method of measurement: Aagglutination test.